Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges
Modelling study backs targeted, not universal, lenacapavir PrEP for pregnancy and breastfeeding
Injectable PrEP in Leeds and London: criteria, approval and continuation
Huge disparities in PrEP uptake across Europe – injectable PrEP largely inaccessible
Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions
Does six-monthly PrEP have a future following the collapse of global HIV funding?
Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding
Once-monthly oral PrEP moves into late-stage trials
